Shares of uniQure N.V. (NASDAQ:QURE) have been given an average recommendation of “Hold” by the nine research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $16.80.
QURE has been the subject of several recent analyst reports. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of uniQure in a research report on Friday. Zacks Investment Research cut shares of uniQure from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Leerink Swann raised their price objective on shares of uniQure from $19.00 to $26.00 in a research report on Tuesday, November 7th. Evercore ISI initiated coverage on shares of uniQure in a research report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price objective for the company. Finally, ValuEngine cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st.
Shares of uniQure (NASDAQ QURE) traded up $0.59 during midday trading on Monday, hitting $15.81. 367,500 shares of the stock were exchanged, compared to its average volume of 304,211. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73. uniQure has a 1-year low of $4.72 and a 1-year high of $21.35.
A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in uniQure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after buying an additional 14,659 shares during the period. Mangrove Partners purchased a new position in uniQure during the second quarter worth about $247,000. OxFORD Asset Management LLP purchased a new position in uniQure during the third quarter worth about $399,000. FMR LLC boosted its stake in uniQure by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after buying an additional 61,650 shares during the period. Finally, Morgan Stanley boosted its stake in uniQure by 14.9% during the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after buying an additional 73,418 shares during the period. 25.07% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “uniQure N.V. (QURE) Given Consensus Rating of “Hold” by Brokerages” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/27/uniqure-n-v-qure-given-consensus-rating-of-hold-by-brokerages.html.
uniQure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.